Our Vision and Mission

For too long, people have lived with the fear and uncertainty of a disease driven by genetic mutations, creating a sense of helplessness and hopelessness. We at Unum know that the only way to eliminate the fear and uncertainty is to improve the treatment paradigm. Our team comes to work each day driven by that opportunity and a sense of urgency to deliver safe and potent precision therapies to treat a range of patients with unmet medical needs with the goal of offering new hope for safe and effective treatment.

Unum’s lead program is PLX9486, a precision kinase inhibitor that targets key mutations in KIT, including the D816V mutation that drives systemic mastocytosis and which can lead to resistance in Gastrointestinal Stromal Tumors (GIST).

purpose icon
“Unum Therapeutics is dedicated to advancing a pipeline of precision kinase inhibitors, starting with PLX9486, to improve outcomes for patients. Our therapies are designed to precisely and potently inhibit targets that drive diseases with significant unmet medical need.”
Chuck Wilson
Chief Executive Officer